Omnipres CH Tablet contains a combination of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg, formulated for the effective management of hypertension. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes diuresis by inhibiting sodium and chloride reabsorption in the distal convoluted tubules of the kidneys, resulting in reduced plasma volume and peripheral vascular resistance. The combination of these two agents provides a complementary mechanism of action, enhancing antihypertensive efficacy while minimizing dose-dependent side effects associated with monotherapy. Omnipres CH is indicated for patients whose blood pressure is not adequately controlled by Olmesartan alone or who require combination therapy to achieve target blood pressure goals. It is essential to monitor renal function, electrolytes, and blood pressure regularly during treatment. Caution is advised in patients with renal impairment, electrolyte imbalances, or a history of hypersensitivity to either component. Omnipres CH Tablet should be used under medical supervision as part of a comprehensive cardiovascular risk management plan.